Bayer offers $7 Billion Roundup Settlement
German Conglomerate makes a bid to end Roundup litigation
Bayer AG has offered to pay more than $7 Billion dollars as part of a settlement to resolve pending and future lawsuits where plaintiffs allege that exposure to Roundup Weedkiller caused their cancer. Bayer is seeking closure of the Roundup the claims after it purchased Monsanto - the American manufacturer of Roundup - several years ago. Bill Anderson, Chief Executive of Bayer, said in a recent interview that he expected the vast majority of plaintiffs with pending claims to agree to the global settlement. Reports indicate that the settlement relates to patient that experienced non-Hodgkin lymphoma, a type of blood cancer.
Roundup was originally developed by Monsanto in the 1970s. The active ingredient in Roundup is glyphosate. In 2015, the International Agency for Research on Cancer, a unit of the World Health Organization, identified glyphosate as a probable human carcinogen. Bayer, as well as the US EPA have disputed that determination.
While Bayer has resolved more than 130,000 Roundup claims, more than 65,000 claims remain active. And additional claims will likely arise in the future when other people exposed to the herbicide learn of their cancer diagnoses. Under the terms of the proposal, anyone exposed to Roundup before February 17, 2026 and diagnosed with non-Hodgkin lymphoma within 16 years of exposure is eligible. Bayer indicated it anticipates paying an additional $3 billion dollars on other Roundup cases.
Bayer is making the move after the United State Supreme Court agreed in January to hear an appeal of a $1.25 million dollar Missouri jury verdict in a Roundup case. Anderson did not address how a loss in the Supreme Court would impact the pending proposal.









